Open AccessMonitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer
Author(s) -
O'Kane Grainne M.,
Labbé Catherine,
Doherty Mark K.,
Young Kelvin,
Albaba Hamzeh,
Leighl Natasha B.
Publication year - 2017
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2016-0164
Subject(s) - medicine , pembrolizumab , nivolumab , adverse effect , tolerability , lung cancer , oncology , chemotherapy , immune system , immunotherapy , monoclonal antibody , intensive care medicine , immunology , antibody
Monoclonal antibodies targeting programmed cell death protein‐1 (PD‐1) represent a new treatment paradigm in non‐small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second‐line chemotherapy. Nevertheless, the adverse events associated with PD‐1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune‐related adverse events in lung cancer patients receiving these agents. Implications for Practice The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multidisciplinary approach. Continued education is important for all physicians to ensure optimal care for patients.